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ABSTRACT
PAM50/Prosigna gene expression-based assay identifies three categorical risk 
of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal 
patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative 
(HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy 
since their risk of distant relapse at 10-years is below 10% with endocrine therapy 
only. In this study, 517 consecutive patients with ER+/HER2- and node-negative 
disease were evaluated for Ki67 and Prosigna. Most of Luminal A tumors (65.6%) and 
ROR-low tumors (70.9%) had low Ki67 values (0-10%); however, the percentage 
of patients with ROR-medium or ROR-high disease within the Ki67 0-10% group 
was 42.7% (with tumor sizes ≤2 cm) and 33.9% (with tumor sizes > 2 cm). Finally, 
we found that the optimal Ki67 cutoff for identifying Luminal A or ROR-low tumors 
was 14%. Ki67 as a surrogate biomarker in identifying Prosigna low-risk outcome 
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patients or Luminal A disease in the clinical setting is unreliable. In the absence of a 
well-validated prognostic gene expression-based assay, the optimal Ki67 cutoff for 
identifying low-risk outcome patients or Luminal A disease remains at 14%.
INTRODUCTION
In the past 10 years, several commercialized 
multigene prognostic tests have been developed to help 
guide treatment decisions in patients with early breast 
cancer [1]. Among them, the PAM50/Prosigna assay 
(NanoString Technologies, Seattle, WA), identifies the 
intrinsic molecular subtype (Luminal A, Luminal B, 
HER2-enriched and Basal-like) and estimates the 10-year 
risk of relapse (ROR) [2–6] using formalin-fixed paraffin-
embedded (FFPE) specimens.
Currently, due to a lack of reimbursement, multigene 
tests are not readily available for all patients in many 
countries. Consequently, the use of immunohistochemistry 
(IHC)-based biomarkers, such as Ki67, has been proposed 
instead, in order to identify patients with low-risk outcome 
who may be safely spared chemotherapy [7–9]. However, 
the 2015 St. Gallen panel proposed that Ki67 scores 
should be interpreted in light of local laboratory values, 
and recommended to use the median expression of each 
lab to define high and low values [9, 10]. In addition, a 
majority of the panel accepted a threshold value of Ki67 
within the range of 20-29%, to distinguish Luminal A from 
Luminal B disease. These recommendations have led to 
confusion regarding how to interpret and use Ki67 scoring 
in the clinical setting.
Here, we aimed to compare the ability of IHC 
Ki67 to identify those patients at a low risk of recurrence 
as defined by the clinically and analytically validated 
commercial version of the PAM50 assay.
RESULTS
Cohort characteristics
Of the 697 patients, a total of 517 (74.2%) had ER+/
HER2-, node-negative disease and Prosigna data available; 
this cohort was the focus of all further analyses (Figure 
1). Prosigna subtype distribution was 56.9% Luminal 
A, 40.8% Luminal B, 1.2% HER2-enriched, and 1.2% 
Basal-like (Table 1, Supplementary Table 1). ROR risk 
group distribution was 38.5% ROR-low, 33.1% ROR-
intermediate and 28.4% ROR-high (Supplementary Table 2). 
Statistically significant differences across the 3 cohorts were 
observed in ROR-groups but not in subtypes distribution. 
(Supplementary Tables 1 and 2).
Figure 1: CONSORT diagram. VHIO, Vall d’Hebron Institute of Oncology; GEICAM, Spanish Breast Cancer Research Group; CBM 
Rome, Università Campus Bio-Medico di Roma.
Oncotarget21932www.impactjournals.com/oncotarget
Subtype and ROR concordance with Ki67
The concordance rates between Prosigna subtype 
(i.e. Luminal A vs. others) and IHC subtype (Luminal 
A-like vs. others) when Ki67 cutoffs of 14% and 20% 
were used were 70.8% (kappa score = 0.43; moderate 
agreement) and 69.1% (kappa score = 0.38; weak 
agreement), respectively. The percentages of Luminal 
A tumors within Ki67 0-10%, 10-20%, 20-30% and 
>30% groups were 81.4%, 51.6%, 29.3% and 15.3%, 
respectively (Table 1 and Supplementary Table 3). The 
distribution of ROR-low tumors within Ki67 0-10%, 
10-20%, 20-30% and >30% groups were 59.5%, 
29.7%, 17.2% and 11.9% respectively. (Table 1 and 
Supplementary Table 4). The percentage of ROR-med/
high patients within the Ki67 0-10% group was 42.7% 
(within tumor size ≤2 cm) and 33.9% (within tumor size 
> 2 cm) (Table 1 and Supplementary Table 4). Although 
not all Luminal A tumors are included in the ROR-low 
group, the ROR-low group is a subset of the Luminal A 
group and consists of only Luminal A tumors.
Identification of Luminal A subtype using Ki67
We compared the distribution of Luminal A and non-
Luminal A tumors as a function of Ki67 using a density 
plot (Figure 2A). As expected, Luminal A tumors were 
more represented within low Ki67 scores and non-Luminal 
A tumors were more represented within high Ki67 scores, 
although considerable overlap was observed. To try to 
identify an optimal Ki67 cutoff to discriminate Luminal 
A versus non-Luminal A, we estimated the performance 
of Ki67 (as a continuous variable). The result revealed an 
area under the receiver operating characteristic (auROC) 
curve of 0.79 and an optimal cutoff of 14% (Figure 3A). It 
is noteworthy to highlight that this is practically the same 
Ki67 cutoff reported by the original work by Cheang and 
colleagues [11], where PAM50 quantitative real time 
polymerase chain reaction (qRT-PCR) based subtyping 
was compared to Ki67 data for the first time.
Identification of ROR-low using Ki67
Similar to subtype identification, we compared the 
distribution of ROR-low, ROR-intermediate and ROR-
high as a function of Ki67 using 2 density plots, one within 
tumor sizes ≤2 cm (Figure 2B) and the other one within 
tumor sizes above 2 cm (Figure 2C). As expected, ROR-
low tumors were more represented within low Ki67 scores 
and ROR-intermediate/high tumors were more represented 
within high Ki67 scores, although considerable overlap 
was observed. To try to identify an optimal Ki67 cutoff to 
Table 1: Distribution of subtypes and ROR within each Ki67 group in 517 patients with HR+/HER2- node-negative 
disease, ROR-med, ROR-medium
Ki67 Group
0-10% 11-20% 21-30% >30%
Intrinsic Subtypes
 Luminal A 193 (81.4%) 63 (51.6%) 29 (29.3%) 9 (15.3%)
 Luminal B 42 (17.7%) 59 (48.4%) 69 (69.7%) 41 (69.5%)
 HER2-enriched 2 (0.8%) 0 1 (1.0%) 3 (5.1%)
 Basal-like 0 0 0 6 (10.2%)
 Total 237 122 99 59
ROR and T≤2cm
 ROR-Low 102 (57.3%) 28 (28.9%) 12 (15.2%) 3 (6.5%)
 ROR-Med 52 (29.2%) 44 (45.4%) 25 (31.6%) 8 (17.4%)
 ROR-High 24 (13.5%) 25 (28.5%) 42 (53.2%) 35 (76.1%)
 Total 178 97 79 46
ROR and T>2cm
 ROR-Low 39 (66.1%) 6 (24.0%) 5 (25.0%) 4 (30.8%)
 ROR-Med 17 (28.8%) 13 (52.0%) 9 (45.0%) 3 (23.1%)
 ROR-High 3 (5.1%) 6 (24.0%) 6 (30.0%) 6 (46.2%)
 Total 59 25 20 13
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Figure 2: Density of the intrinsic subtypes and ROR-groups based on Ki67-positive cells. (A) Density plot in Luminal A 
and non-Luminal A tumors within all patients; (B) Density plot of the 3 ROR-groups within tumor sizes ≤2 cm; (C) Density plot of the 3 
ROR-groups within tumor sizes > 2 cm.
Figure 3: Performance of Ki67 (as a continuous variable) to predict Luminal A or ROR-low disease within HR+/
HER2-  node-negative disease. (A) Predicting Luminal A disease (vs. others); (B) Predicting ROR-low disease (vs. others) within 
tumor sizes ≤ 2 cm; (C) Predicting ROR-low disease (vs. others) within tumor sizes >2 cm tumors. AUC, area under the curve.
Figure 4: Levels of estrogen receptor (ER), progesterone receptor (PR) and Ki67-positive cells across the intrinsic 
subtypes within HR+/HER2-negative node-negative disease. (A) ER; (B) PR; (C) Ki67. P-values were calculated by comparing 
mean values across all groups.
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discriminate ROR-low versus ROR-intermediate/high, we 
estimated the performance of Ki67 (as a continuous variable) 
to identify both groups. The results revealed auROC curves 
within tumor sizes of ≤2 cm and >2 cm of 0.76 and 0.72, 
respectively (Figure 3B-3C). The optimal Ki67 cutoffs for 
identifying ROR-low samples within tumor sizes of ≤2 cm 
and >2 cm were 12% and 15%, respectively.
Identification of Luminal A or ROR-low disease 
using ER and PR levels
Finally, we evaluated if the quantitative expression 
of ER and PR by IHC could help identify either 
Luminal A. None of the two IHC-based biomarkers 
was found useful (Figure 4). However, non-Luminal 
subtypes (i.e. HER2-enriched and Basal-like combined) 
showed statistically significant lower ER (62.6% vs 
88.6%, p-value=0.003), lower PR (13.75% vs 46.5%, 
p-value=0.016) and higher Ki67 (43.1% vs 16.18%, 
p-value<0.001), respectively, compared to both luminal 
subtypes combined.
DISCUSSION
To our knowledge, this is the first report that 
compares ROR and subtype prediction using Prosigna 
and Ki67 in the same sample set. Our results highlight 
the important discrepancy between both biomarkers, and 
challenge the notion that gene expression-based assays 
are not needed in patients with HR+/HER2- disease with 
either low (i.e. <10%) or high (i.e. >20%) Ki67 scores.
The prognostic ability of Prosigna assay has been 
tested in samples from two phase III clinical trials, Arimidex, 
Tamoxifen, Alone or in Combination trial (ATAC) and 
Austrian Breast & Colorectal Cancer Study Group 08 
(ABCSG08) [3, 12], involving a total of 2,485 post-
menopausal patients treated with adjuvant endocrine therapy 
alone for 5 years. The results showed that Prosigna assay 
can identify a group of patients who do not need adjuvant 
chemotherapy due to their low risk (i.e. <10%) of distant 
recurrence at 10 years with endocrine therapy administered 
only [3, 4]. Moreover, Prosigna ROR score and intrinsic 
subtypes are predictors of late recurrence [5, 13] and 
response to multi-agent chemotherapy in the neoadjuvant 
setting [14]. In the recently reported American Society of 
Clinical Oncology (ASCO) Clinical Practice Guidelines, 
Prosigna was identified as an assay with the highest level of 
evidence to guide decisions on adjuvant systemic therapy in 
patients with ER+/HER2- and node-negative tumors [15].
In 2009, Cheang et al. [11] compared Ki67 and gene 
expression, using the qRT-PCR-based PAM50 version, and 
identified 13.25% as the optimal Ki67 cutoff to identify 
Luminal A versus Luminal B disease. The authors noted that 
despite this result, the sensitivity and specificity was around 
75%, meaning that 1 out of 4 patients evaluated would not 
be classified correctly. With similar sensitivity and specificity 
(79.4% and 69.4% respectively), our study confirms that 
~14% is an optimal cutoff for identifying low risk outcome 
patients who can be spared adjuvant chemotherapy when 
gene expression-based assays are not available.
In our view, our findings are important as much 
as it places the Ki67 cutoff at 14%; in 2013 St. Gallen 
International Expert Consensus proposed a Ki67 cutoff 
of 20% together with tumor size and nodal status to help 
identify low risk patients [8], and the 2015 St. Gallen 
panel recommended to use the median expression of 
Ki67 of each lab to define high and low Ki67 values [9, 
10]. Although recommendations from the international 
Ki67 in breast cancer working group have led to 
improvements in reproducing of Ki67 [16], several 
studies have reported a high inter-laboratory variability 
in Ki67 scoring [17, 18].
Our study has several limitations. First, we do not 
have survival outcome data. Thus, we cannot compare the 
true prognostic value of the discrepant cases between the 
two assays. However, the level of analytical and clinical 
validation of the Prosigna assay to identify low-risk 
outcome patients, or Luminal A disease, is higher than the 
levels of validation of Ki67. According to Simon et al. 
criteria [19], Ki67 has not reached level 1 evidence mainly 
due to the suboptimal inter-laboratory reproducibility and 
the lack of a clinically useful cutoff [20]. Second, the 
IHC assessment of Ki67 was done using three different 
assays across the three cohorts of the study. However, the 
results regarding performance and the optimal Ki67 cutoff 
were not affected when adjusted for each type of cohort 
(Supplementary Figures 1, 2 and 3 and Supplementary 
Tables 5, 6 and 7). Third, the number of samples in the 
group of patients with tumors > 2 cm was low.
To conclude, although Ki67 has repeatedly shown 
to be prognostic [21, 22] and predictive of chemotherapy 
response [23, 24], the clinical value of Ki67 in identifying 
low risk outcome patients or Luminal A disease who 
might be safely spared chemotherapy remains uncertain. 
In absence of a well-validated prognostic gene expression-
based assay, the optimal Ki67 cutoff in identifying low 
risk outcome patients (together with tumor size and nodal 
status) or Luminal A disease remains at 14%. However, 
it is worth highlighting that ~50% of patients with 
Luminal A-like disease (e.g. ER+/PR>20%/HER2- and 
Ki67<14%), node-negative and a tumor size above 2 cm, 
will not be classified as ROR-low.
MATERIALS AND METHODS
Cohorts of patients
Prosigna and IHC data were evaluated from 3 
independent cohorts (Spanish Breast Cancer Research 
Group GEICAM/2012-09 prospective study [25], Vall 
d’Hebron Institute of Oncology [VHIO] Translational 
Genomics Lab and Campus Bio-Medico University of 
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Rome [CBM-Rome] Molecular Diagnostic Lab) with a 
total of 697 consecutive postmenopausal women with 
early breast cancer (Figure 1). The GEICAM/2012-09 
was a prospective study of the Spanish Breast 
Cancer Research Group to characterize the impact of 
Prosigna assay in adjuvant treatment decision of 200 
postmenopausal patients with ER+/HER2- breast cancer 
without nodal involvement [25]. VHIO and CBM-Rome 
tested 378 and 119 independent tumor samples (as of 
November 31st, 2016) coming from patients treated in 
clinical practice in Spain and Italy and whose medical 
oncologist decided to order a Prosigna® assay. Similar 
to GEICAM 2012-09 study, we selected patients with 
ER-positive/HER2-negative early breast cancer without 
nodal involvement. All procedures were performed in 
accordance with the ethical standards of the institutional 
and/or national research committee and with the 1964 
Helsinki declaration ethical standards. Informed consent 
was obtained from all individual participants included 
in the study.
Immunohistochemistry
IHC data was obtained from either central review 
(GEICAM/2012-09 and CBM-Rome) or from medical 
reports (VHIO) sent to the pathology laboratory. Ki67 
was assessed by IHC using CONFIRM anti-Ki67 (30-9) 
Rabbit Monoclonal Primary Antibody (Ventana Medical 
System) in the GEICAM/2012-09 cohort. Anti-Ki67 MIB1 
clone antibody (Dako, Glostrup, Denmark) was used in 
the CBM-Rome cohort. No data on Ki67 assessment is 
available for VHIO samples since Ki67 determinations 
were done in multiple local labs. In all samples from 
GEICAM/2012-09 and Campus Bio-Medico, Ki67 
interpretation criteria were done according to the latest 
international recommendations [16].
We defined Luminal A-like or Luminal B-like 
tumors according to the IHC surrogate definitions of 
breast cancer subtypes proposed in the 13th St Gallen 
International Breast Cancer Conference [9]: Luminal 
A-like tumors were defined as HER2-negative, ER-
positive with a low Ki67 assessment (<14%) and 
Luminal B-like tumors were defined as HER2-, ER-
positive with a high Ki67 determination (≥14%). Tumors 
with a low-Ki67 determination (<14%) were considered 
as Luminal B-like tumors if PR was <20% (when PR 
was available) [16]. A cutoff of 20% of Ki67 was also 
explored.
Prosigna assay
FFPE tumors were analyzed using the 
commercialized and standardized PAM50/Prosigna assay 
(NanoString Technologies, Seattle, WA) [1–6]. We have 
followed the specifications of the package insert 2015-07 
LBL-C0223-05.
Statistical analysis
All statistical analyses were performed using R 
version 3.2.2 (www.r-project.org). We used the Cohen's 
kappa coefficient to analyze the agreement between 
IHC-subtypes and Prosigna-subtypes. Quantitative data 
from visual assessment of Ki67 IHC determination (as 
a continuous variable) was compared against Luminal A 
and ROR-low groups as defined by Prosigna. The optimal 
cutoff value for Ki67 was selected by using the auROC 
method and maximizing the Youden index (the sum of 
sensitivity and specificity minus one).
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